A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder

A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder

Alcohol Use Disorder (AUD) is a chronic relapsing disorder affecting an estimated 283 million individuals worldwide, with substantial health and economic consequences. Peroxisome proliferator-activated receptors (PPARs), particularly PPAR-α and PPAR-γ, have shown promise in preclinical studies as po...

Full description

Bibliographic Details
Main Authors:	Barbara J. Mason, David Estey, Amanda Roberts, Giordano de Guglielmo, Olivier George, John Light, Mike Stoolmiller, Susan Quello, Michael Skinner, Farhad Shadan, Adnan Begovic, Mark C. Kyle, R. Adron Harris
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Neurobiology of Stress
Subjects:	Fenofibrate Alcohol use disorder Peroxisome proliferator-activated receptor-alpha Human laboratory study Mouse Rat
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352289523000929

Similar Items

Fenofibrate, a ligand for PPARα, inhibits aromatase cytochrome P450 expression in the ovary of mouse
by: Katsumi Toda, et al.
Published: (2003-02-01)

Therapeutic potential of PPARα agonist in ligature-induced experimental periodontitis
by: Ying Chen, et al.
Published: (2022-03-01)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
by: Treacy Maxwell P, et al.
Published: (2012-09-01)

Peroxisome Proliferator-Activated Receptor Agonists Modulate Neuropathic Pain: a Link to Chemokines?
by: Caroline eFreitag, et al.
Published: (2014-08-01)

Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity
by: Xiaolei Shi, et al.
Published: (2012-11-01)

Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞
by: Steven M. Watkins, et al.
Published: (2002-11-01)

The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
by: Gray Elizabeth, et al.
Published: (2012-04-01)

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice
by: Songling Jiang, et al.
Published: (2022-11-01)

Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice
by: Valentin S, et al.
Published: (2009-02-01)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
by: Montserrat A. de la Rosa Rodriguez, et al.
Published: (2018-06-01)

PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
by: Liu Tiantian, et al.
Published: (2023-11-01)

Amelioration of High Fructose Diet-Induced Insulin Resistance, Hyperuricemia, and Liver Oxidative Stress by Combined Use of Selective Agonists of PPAR-α and PPAR-γ in Rats
by: Mahmoud M. Farag, et al.
Published: (2020-04-01)

Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
by: Tan, Chek Kun, et al.
Published: (2017)

The trans-10, cis-12 isomer of conjugated linoleic acid decreases adiponectin assembly by PPARγ-dependent and PPARγ-independent mechanisms
by: Jessica R. Miller, et al.
Published: (2008-03-01)

Targeting Peroxisome Proliferator Activated Receptor α (PPAR α) for the Prevention of Mitochondrial Impairment and Hypertrophy in Cardiomyocytes
by: Dipak Kar, et al.
Published: (2018-08-01)

PPARα Signaling: A Candidate Target in Psychiatric Disorder Management
by: Simona Scheggi, et al.
Published: (2022-05-01)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
by: Piyush Patel, et al.
Published: (2016-01-01)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
by: Yohei Tomita, et al.
Published: (2020-10-01)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
by: Shigeki Kitamura, et al.
Published: (2023-09-01)

Role of GW0742 A PPARβ/δ Agonist on Coronary Angiogenesis in Control and Diabetic Rats
by: Ensieh Salehi, et al.
Published: (2011-08-01)

Comparison of efficacy and safety of fixed dose combination of rosuvastatin and choline fenofibrate to fixed dose combination of rosuvastatin and fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicentre clinical trial in Indian population
by: Hanmant Barkate, et al.
Published: (2018-01-01)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
by: Ayza MA, et al.
Published: (2020-10-01)

CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
by: V. S. Shirinsky, et al.
Published: (2014-07-01)

PPARα Agonist Suppresses Inflammation after Corneal Alkali Burn by Suppressing Proinflammatory Cytokines, MCP-1, and Nuclear Translocation of NF-κB
by: Yuichiro Nakano, et al.
Published: (2018-12-01)

Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics
by: Rayan G. Alamri, et al.
Published: (2017-01-01)

Pleiotropic effects of PPAR-α – from benchside to bedside
by: I. V. Shirinsky, et al.
Published: (2021-06-01)

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
by: Siyu Tian, et al.
Published: (2021-10-01)

Fenofibrate Protects against Retinal Dysfunction in a Murine Model of Common Carotid Artery Occlusion-Induced Ocular Ischemia
by: Deokho Lee, et al.
Published: (2021-03-01)

Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats
by: Long Li, et al.
Published: (2015-03-01)

Fenofibrate-promoted hepatomegaly and liver regeneration are PPARα-dependent and partially related to the YAP pathway
by: Shicheng Fan, et al.
Published: (2024-07-01)

Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway
by: Tong Zhou, et al.
Published: (2022-12-01)

Residual Cardiovascular Risk in Diabetic Patients: The Role of Fibrate Statin Combination
by: Angelos Liontos, et al.
Published: (2014-10-01)

A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia
by: Meenakshi Lella, et al.
Published: (2013-01-01)

Peroxisome Proliferator-Activated Receptor α Activation Protects Retinal Ganglion Cells in Ischemia-Reperfusion Retinas
by: Fei Yao, et al.
Published: (2021-12-01)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
by: Claudia Sagheddu, et al.
Published: (2021-10-01)

Evaluation of the Relationship between Peroxisome Proliferator Receptors (PPARα, PPARγ, and PPARδ) Expression and Carcinoembryonic Antigen (CEA) in Patients with Colorectal Cancer
by: Musa Yaghoubizadeh, et al.
Published: (2022-08-01)

Activation of PPARα by Fenofibrate Attenuates the Effect of Local Heart High Dose Irradiation on the Mouse Cardiac Proteome
by: Omid Azimzadeh, et al.
Published: (2021-12-01)

Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
by: Zirui Qiu, et al.
Published: (2022-10-01)

Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
by: Olga Nikolaevna Tkacheva, et al.
Published: (2010-03-01)

Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
by: Junko Oya, et al.
Published: (2023-11-01)